PMID- 21550727
OWN - NLM
STAT- MEDLINE
DCOM- 20120316
LR  - 20161125
IS  - 1532-1967 (Electronic)
IS  - 0305-7372 (Linking)
VI  - 38
IP  - 2
DP  - 2012 Apr
TI  - Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast 
      cancer.
PG  - 143-51
LID - 10.1016/j.ctrv.2011.03.006 [doi]
AB  - BACKGROUND: Microtubule-targeted agents are one of the most common classes of 
      chemotherapeutic drug for the treatment of breast cancer. Limitations of current 
      microtubule-targeted agents such as primary or secondary resistance of cancer 
      cells and side effects like neuropathy prompted the discovery and introduction of 
      newer more effective drugs. This review aims to provide a summary of the novel 
      halichondrin B analog eribulin mesylate (E7389) and illustrate where it is placed 
      in the treatment arena versus other agents that are approved or are currently in 
      various stages of clinical development. METHODS: Preclinical and clinical trial 
      (phases I-III) data for eribulin were obtained from scientific journals and 
      meeting abstracts, posters, and oral presentations. The use of current and other 
      emerging microtubule inhibiting agents in breast cancer was also surveyed and 
      briefly reviewed. RESULTS: Eribulin mesylate at a dose of 1.4 mg/m(2) given on 
      days 1 and 8 of a 21-day cycle increased overall survival in patients with 
      metastatic breast cancer (MBC). Neutropenia, fatigue, alopecia, nausea and anemia 
      were common adverse events (AEs) associated with eribulin in clinical studies. A 
      low incidence of peripheral neuropathy was also associated with eribulin in 
      clinical studies (21-26%). Other emerging microtubule targeted agents, such as 
      vinflunine and larotaxel, also reported efficacy in patients with MBC who had 
      received prior chemotherapy, with grade 3/4 neutropenia being the most common AEs 
      for both agents. CONCLUSIONS: Eribulin mesylate offers clinical activity in 
      advanced breast cancer through improved overall survival, its favorable 
      side-effect profile and convenience of preparation and administration.
CI  - Copyright (c) 2011 Elsevier Ltd. All rights reserved.
FAU - Cortes, Javier
AU  - Cortes J
AD  - Department of Oncology, Vall d Hebron University Hospital, Barcelona, Spain. 
      jacortes@vhio.net
FAU - Montero, Alberto J
AU  - Montero AJ
FAU - Gluck, Stefan
AU  - Gluck S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20110508
PL  - Netherlands
TA  - Cancer Treat Rev
JT  - Cancer treatment reviews
JID - 7502030
RN  - 0 (Furans)
RN  - 0 (Ketones)
RN  - 0 (Tubulin Modulators)
RN  - LR24G6354G (eribulin)
SB  - IM
MH  - Breast Neoplasms/*drug therapy/pathology
MH  - Female
MH  - Furans/adverse effects/chemistry/*therapeutic use
MH  - Humans
MH  - Ketones/adverse effects/chemistry/*therapeutic use
MH  - Tubulin Modulators/adverse effects/chemistry/*therapeutic use
EDAT- 2011/05/10 06:00
MHDA- 2012/03/17 06:00
CRDT- 2011/05/10 06:00
PHST- 2010/12/06 00:00 [received]
PHST- 2011/03/23 00:00 [revised]
PHST- 2011/03/28 00:00 [accepted]
PHST- 2011/05/10 06:00 [entrez]
PHST- 2011/05/10 06:00 [pubmed]
PHST- 2012/03/17 06:00 [medline]
AID - S0305-7372(11)00060-0 [pii]
AID - 10.1016/j.ctrv.2011.03.006 [doi]
PST - ppublish
SO  - Cancer Treat Rev. 2012 Apr;38(2):143-51. doi: 10.1016/j.ctrv.2011.03.006. Epub 
      2011 May 8.